Neurological Disease - Myriad RBM
 
 

Bibliography

Neurological Disease

2014

Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment (2014) de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS, Bahn S Schizophr Res. 2014 Feb 26. pii: S0920-9964(14)00071-1
 
Therapy Indications
 

Inflammatory Molecular Signature Associated With Infectious Agents in Psychosis (2014) Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, Leweke FM, Yolken RH, Sawa A Schizophr Bull. 2014 Apr 17. [Epub ahead of print]
 
Therapy Indications
 

Multiplex Screen of Serum Biomarkers in (2014) Jeffrey Statlanda, Colleen M. Donlin-Smithb, Stephen J. Tapscottc, Silvere van der Maarel, Rabi Tawil Journal of Neuromuscular Diseases DOI 0.3233/JND-140034
 
Therapy Indications
 

An Anti-Neuroinflammatory That Targets Dysregulated Glia Enhances the Efficacy of CNS-Directed Gene Therapy in Murine Infantile Neuronal Ceroid Lipofuscinosis. (2014) Shannon L. Macauley, Andrew M.S. Wong, Charles Shyng, David P. Augner, Joshua T. Dearborn, Yewande Pearse, Marie S. Roberts, Stephen C. Fowler, Jonathan D. Cooper, D. Martin Watterson, and Mark S. Sands Journal of Neuroscience 2014 Sep 24;34(39):13077-82. doi: 10.1523/JNEUROSCI.2518-14.2014.
 
Therapy Indications
 

The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease (2014) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE J Alzheimers Dis. 2014 Feb 20. [Epub ahead of print]
 
Therapy Indications
 

MRI signal and texture features for the prediction of MCI to Alzheimer's disease progression (2014) Martínez -Torteya A, Rodríguez-Rojas J, Celaya-Padilla JM, Galván-Tejada JI, Treviño V, Tamez-Peña JG Proc. SPIE 9035
 
Therapy Indications
 

Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment (2014) Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J Alzheimer's Research & Therapy 2014, 6:36
 
Therapy Indications
 

Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender (2014) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE Dementia and Geriatric Cognitive Disorders Vol. 38, No. 5-6, 2014
 
Therapy Indications
 

Vitamin D Binding Protein as a Serum Biomarker of Alzheimer's Disease. (2014) Bishnoi RJ, Palmer RF, Royall DR. Journal of Alzheimer's Disease 2014 Jul 30. [Epub ahead of print]
 
Therapy Indications
 

Ethnicity Moderates Dementia's Biomarkers. (2014) Royall DR, Palmer RF Journal of Alzheimer's Disease 2014 Jul 30. [Epub ahead of print]
 
Therapy Indications
 

Oxidative Stress, Testosterone, and Cognition among Caucasian and Mexican-American Men with and without Alzheimer's Disease (2014) Cunningham RL1, Singh M1, O'Bryant SE2, Hall JR3, Barber RC J Alzheimers Dis. 2014 Feb 4. [Epub ahead of print]
 
Therapy Indications
 

Phosphorylated tau-Aß42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer's Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. (2014) Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer’s Disease Neuroimaging Initiative Biol Psychiatry. 2014 Jan 19. pii: S0006-3223(14)00018-3
 
Therapy Indications
 

Are Blood-Based Protein Biomarkers for Alzheimer's Disease also Involved in Other Brain Disorders? A Systematic Review (2014) Justin Tao Wen Chiam, Richard James Butler Dobson, Steven John Kiddle, Martina Sattlecker Journal of Alzheimer's Disease 2014 Aug 5; 1875-8908 doi:10.3233/JAD-140816
 
Product Associations
 
 
Therapy Indications
 

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach (2014) Inamdar A, Merlo-Pich E, Gee M, Makumi C, Mistry P, Robertson J, Steinberg E, Zamuner S, Learned S, Alexander R, Ratti E J Psychopharmacol. 2014 Apr 2. [Epub ahead of print]
 
Therapy Indications
 

Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. (2014) van Beveren NJ, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L, Bahn S. Translational Psychiatry 2014 Aug 26;4:e430. doi: 10.1038/tp.2014.52.
 
Therapy Indications
 

Back To Top

2013

Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection (2013) Huckans M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, Kolessar M, Kriz D, Anderson JR, Vandenbark AA, Loftis JM Brain and Behavior

The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans (2013) O'Bryant SE, Johnson L, Edwards M, Soares H, Devous MD, Ross S, Rohlfing G, Hall J J Alzheimers Dis. 2013;34(3):701-6
 
Therapy Indications
 

RANTES has a potential to play a neuroprotective role in an autocrine/paracrine manner after ischemic stroke (2013) Tokamia H, Ago T, Sugimori H, Kuroda J, Awano H, Suzuki K, Kiyohara Y, Kamouchi M, Kitazono T Brain Research, Available online 18 April 2013
 
Therapy Indications
 

Application of meta-analysis methods for identifying proteomic expression level differences (2013) Amess B, Kluge W, Schwarz E, Haenisch F, Alsaif M, Yolken RH, Leweke FM, Guest PC, Bahn S. Proteomics. 2013 Apr 14.

Biomarkers of Alzheimer's Disease Among Mexican Americans (2013) O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R J Alzheimers Dis. 2013 Jan 11. [Epub ahead of print]
 
Therapy Indications
 

The effects of stress on hypothalamic-pituitary-adrenal (HPA) axis function in subjects with schizophrenia (2013) Guest FL, Martins-de-Souza D, Rahmoune H, Bahn S, Guest PC Rev Psiq Clín. 2013;40(1):20-7
 
Product Associations
 
 
Therapy Indications
 

A blood-based predictor for neocortical Aß burden in Alzheimer’s disease: results from the AIBL study (2013) Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group Mol Psychiatry. 2013 Apr 30
 
Therapy Indications
 

Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1 (2013) Cologna SM, Cluzeau CV, Yanjanin NM, Blank PS, Dail MK, Siebel S, Toth CL, Wassif CA, Lieberman AP, Porter FD. J Inherit Metab Dis. 2013 May 8.
 
Therapy Indications
 

Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential (2013) Johnston J, Hu W, Fardo D, Greco S, Perry G, Montine T, Trojanowski J, Shaw L, Ashford J, Tezapsidis N, For The Alzheimer's Disease Neuroimaging Initiative Curr Alzheimer Res. 2013 Dec 11. [Epub ahead of print]
 
Therapy Indications
 

SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy (2013) Kobayashi DT, Shi J, Stephen L, Ballard KL, Dewey R, Mapes J, Chung B, McCarthy K, Swoboda KJ, Crawford TO, Li R, Plasterer T, Joyce C; Biomarkers for Spinal Muscular Atrophy Study Group, Chung WK, Kaufmann P, Darras BT, Finkel RS, Sproule DM, Martens WB, McDermott MP, De Vivo DC; Pediatric Neuromuscular Clinical Research Network, Walker MG, Chen KS PLoS ONE 8(4): e60113.
 
Therapy Indications
 

CSF protein biomarkers predicting longitudinal reduction of CSF ß-amyloid42 in cognitively healthy elders (2013) Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, Tosun D, Weiner M Transl Psychiatry. 2013 Aug 20;3:e293
 
Product Associations
 
 
Therapy Indications
 

Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain (2013) Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S World J Biol Psychiatry. 2013 Sep 3. [Epub ahead of print]
 
Therapy Indications
 

Identification of a molecular profile associated with immune status in first onset schizophrenia patients (2013) Herberth M, Rahmoune H, Schwarz E, Koethe D, Harris LW, Kranaster L, Witt SH, Spain M, Barnes A, Schmolz M, Leweke MF, Guest PC, Bahn S Clin Schizophr Relat Psychoses. 2013 Feb 8:1-14

Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. (2013) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, Singh M, O'Bryant SE. Journal of Alzheimer's Disease
 
Therapy Indications
 

Newborn screening for autism: in search of candidate biomarkers (2013) Mizejewski GJ, Lindau-Shepard B, Pass KA Biomark Med. 2013 Apr;7(2):247-60
 
Therapy Indications
 

Impaired glycemia increases disease progression in mild cognitive impairment (2013) Morris JK, Vidoni ED, Honea RA, Burns JM Neurobiology of Aging, Available online 23 October 2013

Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI (2013) Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM, Trojanowski JQ, Davatzikos C PLoS One. 2013;8(2):e55531
 
Therapy Indications
 

Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis (2013) Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C JAMA Neurol. 2013 Aug 1;70(8):1017-21

Plasma apolipoprotein A1 as a biomarker for parkinson's disease (2013) Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS Ann Neurol. 2013 Feb 27
 
Therapy Indications
 

Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without GBA Mutations (2013) Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig HI, Lee V M-Y, Van Deerlin VM, Leverenz JB, Siderowf AD, Trojanowski JQ, Zabetian CP, Chen-Plotkin A JAMA Neurol. 2013;():1-7
 
Product Associations
 
 
Therapy Indications
 

Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders (2013) Ernst A, Sharma AN, Elased KM, Guest PC, Rahmoune H, Bahn S Transl Psychiatry. 2013 May 28;3:e263

Does ethnicity moderate dementia's biomarkers (2013) Royall DR, Palmer RF; Texas Alzheimer's Research and Care Consortium Neurobiol Aging. 2013 Sep 18. pii: S0197-4580(13)00340-0
 
Therapy Indications
 

Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3ß signaling in bipolar patients (2013) Haenisch F, Alsaif M, Guest PC, Rahmoune H, Dickerson F, Yolken R, Bahn S Journal of Affective Disorders
 
Therapy Indications
 

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease (2013) Guo L, Alexopoulos P, Perneczky R European Archives of Psychiatry and Clinical Neuroscience
 
Therapy Indications
 

Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults (2013) Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack Jr. CR, Tosun D, Weiner M, Alzheimer's Disease Neuroimaging Initiative Neurobiology of Aging, Available online 1 October 2013
 
Therapy Indications
 

Back To Top

2012

Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects (2012) Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, Vanattou-Saifoudine N, Leweke FM, Guest PC, Bahn S World J Biol Psychiatry. 2012 Jan 17. [Epub ahead of print]
 
Therapy Indications
 

Proteomic analysis of the maternal protein restriction rat model for schizophrenia: Identification of translational changes in hormonal signalling pathways and glutamate neurotransmission (2012) Guest PC, Urday S, Ma D, Stelzhammer V, Harris LW, Amess B, Pietsch S, Oheim C, Ozanne SE, Bahn S Proteomics. 2012 Oct 16
 
Therapy Indications
 

Differences in the Association of Peripheral Insulin and Cognitive Function in Non-Diabetic Alzheimer's Disease Cases and Normal Controls (2012) Pavlik V, Massman P, Barber R, Doody R J Alzheimers Dis. 2012 Dec 14. [Epub ahead of print]

Analysis of serum and plasma identifies differences in molecular coverage, measurement variability and candidate biomarker selection (2012) Alsaif M, Guest PC, Schwarz E, Reif A, Kittel-Schneider S, Spain M, Rahmoune H, Bahn S Proteomics Clin Appl. 2012 May 29
 
Therapy Indications
 

Comparison of protein concentrations in serum versus plasma from Alzheimer’s patients (2012) Huebinger RM, Xiao G, Wilhelmsen KC, Diaz-Arrastia R, Zhang F, O’Bryant SE, Barber RC Advances in Alzheimer’s Disease Vol.1, No.3, 51-58 (2012)
 
Therapy Indications
 

Plasma biomarkers of depressive symptoms in older adults (2012) Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, Kim EJ, Wolk DA, Bennett DA, Chen-Plotkin A, Grossman M, Hu W, Lee VMY, Mackin RS, Trojanowski JQ, Wilson RS, Shaw LM Translational Psychiatry (2012) 2, e65;
 
Therapy Indications
 

Neural progenitor cells regulate microglia functions and activity (2012) Mosher KI, Andres RH, Fukuhara T, Bieri G, Hasegawa-Moriyama M, He Y, Guzman R, Wyss-Coray T Nat Neurosci. 2012 Nov;15(11):1485-7
 
Therapy Indications
 

Biomarkers and Depressive Symptoms in Older Women with and without Cognitive Impairment (2012) Hall JR, Johnson LA, Vo HT, Barber RC, Winter AS, O’Bryant SE Journal of Behavioral and Brain Science, 2012, 2, 276-281
 
Therapy Indications
 

Associations between gonadotropins, testosterone and ß amyloid in men at risk of Alzheimer's disease (2012) Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN Mol Psychiatry. 2012 Oct 23
 
Therapy Indications
 

Plasma biomarkers for Alzheimer's disease: much needed but tough to find (2012) Bazenet C, Lovestone S Biomark Med. 2012 Aug;6(4):441-54
 
Therapy Indications
 

Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease (2012) Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; for the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project Arch Neurol. 2012 Jul 16:1-8
 
Therapy Indications
 

Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease (2012) Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; for the Alzheimer's Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group Arch Neurol. 2012 Jul 16:1-8
 
Therapy Indications
 

Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease (2012) Barber RC, Edwards MI, Xiao G, Huebinger RM, Diaz-Arrastia R, Wilhelmsen KC, Hall JR, OBryant SE, for the Texas Alzheimer's Research and Care Consortium Dement Geriatr Cogn Disord Extra 2012;2:353-360
 
Therapy Indications
 

Proteomic approaches to unravel the complexity of schizophrenia (2012) Martins-de-Souza D, Guest PC, Rahmoune H, Bahn S Expert Rev Proteomics. 2012 Feb;9(1):97-108
 
Therapy Indications
 

Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset (2012) Johnstone D, Milward EA, Berretta R, Moscato P PLoS One. 2012;7(4):e34341
 
Therapy Indications
 

Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals (2012) Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS PLoS One. 2012;7(6):e34078
 
Therapy Indications
 

The Relation between Inflammation and Neuropsychological Test Performance (2012) Balldin VH, Hall JR, Barber RC, Hynan L, Diaz-Arrastia R, O’Bryant SE International Journal of Alzheimer’s Disease Volume 2012, Article ID 703871
 
Therapy Indications
 

Quantitative Proteomic Analysis of Niemann-Pick Disease, Type C1 Cerebellum Identifies Protein Biomarkers and Provides Pathological Insight (2012) Cologna SM, Jiang X-S, Backlund PS, Cluzeau CVM, Dail MK, Yanjanin NM, Siebel S, Toth CL, Jun H, Wassif CA, Yergey AL, Porter FD PLoS ONE 7(10): e47845
 
Therapy Indications
 

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype (2012) Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM Arch Neurol. 2012 Jun 1;69(6):757-64
 
Therapy Indications
 

Cerebrospinal fluid APOE levels, an endophenotype for genetic studies for Alzheimer's disease (2012) Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A; the Alzheimer’s Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM Hum Mol Genet. 2012 Jul 20. [Epub ahead of print]
 
Therapy Indications
 

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aß amyloidosis (2012) Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM J Exp Med. 2012 Nov 5. [Epub ahead of print]
 
Therapy Indications
 

Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study (2012) Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, Li X, Guo Y, Li RH, Trachtenberg F, Forrest SJ, Kobayashi DT, Chen KS, Joyce CL, Plasterer T PLoS ONE 7(4): e35462
 
Therapy Indications
 

Cardiovascular risk factors, cortisol, and amyloid-ß deposition in Alzheimer's Disease Neuroimaging Initiative (2012) Toledo JB, Toledo E, Weiner MW, Jack CR Jr, Jagust W, Lee VM, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 2012 Nov;8(6):483-9
 
 

Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease (2012) Llano DA, Devanarayan V, Simon AJ; The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimer Dis Assoc Disord. 2012 Sep 27
 
Therapy Indications
 

Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly (2012) Rajagopalan P, Refsum H, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative Neurobiol Aging. 2012 Nov 19. pii: S0197-4580(12)00533-7

Plasma Based Markers of [(11)C] PiB-PET Brain Amyloid Burden (2012) Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R; for the Alzheimers Disease Neuroimaging Initiative PLoS One. 2012;7(9):e44260.
 
Therapy Indications
 

Adipocytokine signaling is altered in flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression (2012) Wilhelm CJ, Choi D, Huckans M, Manthe L, Loftis JM Pharmacol Biochem Behav. 2012 Nov 12. pii: S0091-3057(12)00312-7
 
Product Associations
 
 
Therapy Indications
 

Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations (2012) Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G Dement Geriatr Cogn Disord. 2012;33(4):219-25
 
Therapy Indications
 

Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease (2012) Hall JR, Johnson LA, Barber RC, Vo HT, Winter AS, O'Bryant SE J Alzheimers Dis. 2012 May 9. [Epub ahead of print]
 
Therapy Indications
 

Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients (2012) Stelzhammer V, Guest PC, Rothermundt M, Sondermann C, Michael N, Schwarz E, Rahmoune H, Bahn S Eur Neuropsychopharmacol. 2012 Nov 22. pii: S0924-977X(12)00303-3
 
Therapy Indications
 

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H; Alzheimer's Disease Neuroimaging Initiative Neurology. 2012 Aug 28;79(9):897-905
 
Therapy Indications
 

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients (2012) Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S Translational Psychiatry (2012) 2, e82
 
Therapy Indications
 

Neuroinflammatory phenotype in early Alzheimer's disease (2012) Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM Neurobiol Aging. 2012 Oct 9. pii: S0197-4580(12)00468-X

Back To Top

2011

Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival (2011) Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S, Ruh H, Rahmoune H, Kranaster L, Schoenborn T, Leweke MF, Guest PC, Bahn S Proteomics 11: 94-105.

Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net (2011) Shen L, Kim S, Qi Y, Inlow M, Swaminathan S, Nho K, Wan J, Risacher SL, Shaw LM, Trojanowski JQ, Weiner M, Saykin AJ, ADNI Lecture Notes in Computer Science, 2011, Volume 7012/2011, 27-34
 
Therapy Indications
 

Plasma clusterin and the risk of Alzheimer disease (2011) Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM JAMA. 305: 1322-6
 
Therapy Indications
 

Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses (2011) Lewandowski KE, Cohen BM, Keshavan MS, Ongür D Schizophr Res. 2011 Oct 11. [Epub ahead of print]
 
Therapy Indications
 

Biomarkers and Depressive Symptoms in a Sample of Cognitively Intact and Alzheimer’s Disease Elderly Males (2011) Hall JR, Vo HT, Johnson LA, Winter S, Barber RC, O’Bryant SE Neuroscience & Medicine, 2011, 2, 306-312
 
Therapy Indications
 

Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome (2011) Britschgi M, Rufibach K, Bauer Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T Mol Cell Proteomics. 2011 Jul 8. [Epub ahead of print]
 
Therapy Indications
 

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB (2011) Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Lassmann H, Szymkowski DE, Probert L Brain. 2011 Sep;134(Pt 9):2722-35

Identification of a biological signature for schizophrenia in serum (2011) Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S Mol Psychiatry. 2012 May;17(5):494-502
 
Therapy Indications
 

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression (2011) Dreimüller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadic A Neuropharmacology. 2011 Jul 22. [Epub ahead of print]
 
Therapy Indications
 

Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during Experimental Autoimmune Encephalomyelitis (2011) Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, Arnett HA, Prieto AL, Tsiperson V, Shafit-Zagardo B J Neuroinflammation. 2011 May 15;8:49

The ageing systemic milieu negatively regulates neurogenesis and cognitive function (2011) Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Després S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T Nature. 2011 Aug 31;477(7362):90-4
 
Therapy Indications
 

Inflammatory signaling in Alzheimer disease and depression (2011) Barber, R Cleveland Clinic Journal of Medicine vol. 78 Suppl 1 S47-S49
 
Product Associations
 

Measurement of Aß1-42 in Cerebrospinal Fluid is Influenced by Matrix Effects (2011) Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K J Neurochem. 2011 Oct 25.
 
Therapy Indications
 

A Longitudinal Analysis of Circulating Stress-Related Proteins and Chronic Ethanol Self-Administration in Cynomolgus Macaques (2011) Helms CM, Messaoudi I, Jeng S, Freeman WM, Vrana KE, Grant KA Alcohol Clin Exp Res. 2011 Dec 5. [Epub ahead of print]
 
Therapy Indications
 

A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI (2011) O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R; for the Texas Alzheimer's Research & Care Consortium; for the Alzheimer's Disease Neuroimaging Initiative PLoS One. 2011;6(12):e28092. Epub 2011 Dec 7.
 
Therapy Indications
 

Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer’s Disease (2011) Öhrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A Dement Geriatr Cogn Disord Extra 1: 31–42.
 
Therapy Indications
 

Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis (2011) Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM PLoS One. 2011 Apr 19;6(4):e18850
 
Therapy Indications
 

Building an integrated neurodegenerative disease database at an academic health center (2011) Xie SX, Baek Y, Grossman M, Arnold SE, Karlawish J, Siderowf A, Hurtig H, Elman L, McCluskey L, Van Deerlin V, Lee VM, Trojanowski JQ Alzheimers Dement. 2011 Jul;7(4):e84-e93
 
Therapy Indications
 

Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy (2011) Stelzhammer V, Rothermundt M, Guest PC, Michael N, Sondermann C, Kluge W, Martins-de-Souza D, Rahmoune H, Bahn S Proteomics Clin Appl. 2011 Oct 17.
 
Product Associations
 
 
Therapy Indications
 

The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis (2011) Macauley SL, Pekny M, Sands MS J Neurosci. 2011 Oct 26;31(43):15575-85
 
Therapy Indications
 

Depression and Brain-Derived Neurotrophic Factor Levels in Alzheimer’s Disease (2011) Hall JR, O’Bryant SE, Johnson L, Barber RC Neuroscience & Medicine, 2, 43-47
 
Therapy Indications
 

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies (2011) O'Gorman C, Kapur S, Kolluri S, Kane J Hum Psychopharmacol. 2011 Jun 2. [Epub ahead of print]
 
Therapy Indications
 

Identification of a blood-based biological signature in subjects with psychiatric disorders (2011) Schwarz E, Guest PC, Rahmoune H, Martins-de-Souza D, Niebuhr DW, Weber NS, Cowan DN, Yolken RH, Spain M, Barnes A, Bahn S World J Biol Psychiatry. 2012 Dec;13(8):627-32
 
Therapy Indications
 

Back To Top

2010

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease (2010) Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ Ann Neurol. Nov 29. [Epub ahead of print]
 
Therapy Indications
 

Magnetic Resonance Imaging Predictors of Treatment Response in First-Episode Schizophrenia (2010) Szeszko PR, Narr KL, Phillips OR, McCormack J, Sevy S, Gunduz-Bruce H, Kane JM, Bilder RM, Robinson DG Schizophr Bull. Nov 17. [Epub ahead of print]
 
Therapy Indications
 

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response (2010) Kovalchin J, Krieger J, Genova M, Collins K, Augustyniak M, Masci A, Hittinger T, Kuca B, Edan G, Braudeau C, Rimbert M, Patel U, Mascioli E, Zanelli E J Neuroimmunol. 225: 153-63.

A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease (2010) O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R; for the Texas Alzheimer's Research Consortium Arch Neurol 67: 1077-1081.
 
Therapy Indications
 

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers (2010) Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T J Proteomics73: 1117-32.
 
Product Associations
 

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease (2010) Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Acta Neuropathol 120: 385-99.
 
Therapy Indications
 

Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia (2010) Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, (JM) van Beveren N, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S Biomark Insights5: 39–47.
 
Therapy Indications
 

Identification of targeted analyte clusters for studies of schizophrenia. (2010) Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrania Y, Wayland MT, Lió P, Bahn S Mol Cell Proteomics 9: 510-522.
 
Therapy Indications
 

Decreased C-Reactive Protein Levels in Alzheimer Disease. (2010) O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R J Geriatr Psychiatry Neurol 23: 49-53.
 
Therapy Indications
 

Individual Differences in Hyperlipidemia and Vitamin E Status in Response to Chronic Alcohol Self-Administration in Cynomolgus Monkeys (2010) Lebold KM, Grant KA, Freeman WM, Wiren KM, Miller GW, Kiley C, Leonard SW, Traber MG Alcohol Clin Exp Res. 2010 Nov 30. [Epub ahead of print]

Sex-specific serum biomarker patterns in adults with Asperger's syndrome (2010) Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, Ruta L, Kent L, Spain M, Baron-Cohen S, Bahn S Mol Psychiatry. 2010 Sep 28. [Epub ahead of print]
 
Therapy Indications
 

Novel CSF biomarkers for frontotemporal lobar degenerations (2010) Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Neurology 75: 2079-86.
 
Therapy Indications
 

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment (2010) Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Acta Neuropathol 119: 669-678.
 
Therapy Indications
 

Classification of Alcohol Abuse by Plasma Protein Biomarkers. (2010) Freeman WM, Salzberg AC, Gonzales SW, Grant KA, Vrana KE Biol Psychiatry 68: 219-22.
 
Therapy Indications
 

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. (2010) Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P PLoS ONE 5: e9166.
 
Therapy Indications
 

Back To Top

2009

Brain-derived neurotrophic factor levels in Alzheimer's disease. (2009) O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L, Cullum CM, Diaz-Arrastia R; Texas Alzheimer's Research Consortium J Alzheimers Dis 17: 337-341.
 
Therapy Indications
 

Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels (2009) Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M Ann N Y Acad Sci. 1180 :56-67.
 
Therapy Indications
 

Matrix metalloproteinases during and outside of migraine attacks without aura. (2009) Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J Cephalalgia 30: 303-310.
 
Therapy Indications
 

Back To Top

2008

Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. (2008) Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM J Neurosci 28: 14156-14164.
 
Therapy Indications